Cipla Q1 Results: The profit beat the ET Now Poll estimates of Rs 1,071 crore. Revenue from operations in the reporting period increased 6% year-on-year to Rs 6,694 crore. EBITDA saw a 14% year-on-year increase, reaching Rs 1,716 crore. This growth was primarily driven by the One India business' branded prescription division, which experienced a 10% growth. This growth was particularly strong in focused chronic therapies like respiratory, cardiac, and urology, outpacing the market. The overall chronic mix in the portfolio also improved by 106 basis points year-on-year, reaching 61.5%.
